Vor Biopharma (VOR) Operating Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Expenses data on file, last reported at $35.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $35.2 million, up 5.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $373.5 million (up 205.78% YoY), and the FY2025 annual result was $371.6 million, up 206.67% from the prior year.
• Operating Expenses slipped to $35.2 million in Q1 2026 per VOR's latest filing, from $36.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $274.3 million in Q2 2025 and troughed at $21.8 million in Q2 2022.
• A 5-year average of $44.0 million and a median of $30.4 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses retreated 19.26% in 2024, then jumped 844.67% in 2025.
• A 5-year view of Operating Expenses shows it stood at $24.7 million in 2022, then climbed by 13.75% to $28.1 million in 2023, then advanced by 11.33% to $31.3 million in 2024, then advanced by 14.85% to $36.0 million in 2025, then retreated by 2.22% to $35.2 million in 2026.
• Business Quant data shows VOR's Operating Expenses at $35.2 million in Q1 2026, $36.0 million in Q4 2025, and $28.1 million in Q3 2025.